Navigation Links
Alexza to Webcast Investor and Analyst Day Presentations
Date:4/22/2008

MOUNTAIN VIEW, Calif., April 22 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will host a live audio webcast of presentations given at the Company's Investor and Analyst Day on Tuesday, April 29th, 2008. Leading medical experts will discuss the Phase 1 and Phase 2 results of the Company's clinical trials, provide an overview of the Phase 3 trial design for AZ-004 (Staccato(R) loxapine), and discuss the role that AZ-004 may play in treating acute agitation in schizophrenic or bipolar disorder patients. Alexza senior management will also provide an overview of Alexza's other clinical stage product candidates.

What: Presentations (Audio & Slides)

Who: Dr. Michael Allen - University of Colorado Health Sciences

Center

Associate Professor of Psychiatry

Director, Emergency and Consultation Psychiatry

Co-Director, Mood Disorders Program

Past President and Trustee, American Association for

Emergency Psychiatry

Dr. Carol Tamminga -- University of Texas Southwestern

Medical Center

Professor of Psychiatry

Vice Chair for Clinical Research

Chief of Translational Neuroscience Research in

Schizophrenia

Communities Foundation of Texas Chair in Brain Science

When: Tuesday, April 29th, 2008 at 12:15-3:00 p.m. EDT

Where: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-

eventDetails&c=196151&eventID=1831771

or

http://www.alexza.com/investor_section/news_events.php

How: Live over the Internet -- Simply log on to the Web at the

address above and register for the event (approximately 10

minutes beforehand)

If you are unable to participate during the live webcast, the call will be archived on Alexza's website at http://www.alexza.com.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated webcast and presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings. Forward-looking statements contained in the webcast and presentations are made as of their date of presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
3. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
4. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
5. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
6. Johnson & Johnson to Webcast Annual Meeting of Shareholders
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
9. ResMed to Webcast Third Quarter 2008 Earnings Conference Call
10. CTG Announces 2008 First Quarter Conference Call and Webcast Information
11. MSA Schedules First Quarter Earnings Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... Students interested in video can get a jump start on their education ... $1,000 scholarship and have his or her video posted on the GenCure website and ... with the winner announced on June 9. , The competition is designed to help ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full ... clients in the California Bay Area, is launching a charity drive to raise awareness ... Heart disease is the primary killer of adult men and women in America, and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” ... consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 ... of those children. James saw firsthand the effect of the critical funding gap for ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited ... compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and ... pleasure to welcome back Dr. Kim to the CDG team” said President and Managing ...
(Date:1/19/2017)... ... January 19, 2017 , ... Each ... Surgery Symposium, a conference where hundreds of surgeons from over fifteen different countries ... topics from cosmetic breast augmentation to breast reconstruction for breast cancer ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... -- Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market ... $5,491 million by 2022, growing at a CAGR of 5.8% from 2016 ... the leading regional market in global vital signs monitoring devices industry. The ...
(Date:1/18/2017)... Jan. 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), the ... partnership with Hyatt Place Nashville/Downtown to deliver the best ... sleep therapy machines in over two hundred of its ... important parts of having a great stay is sleeping ... Hyatt Place Nashville/Downtown. "We,re pleased to be able to ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
Breaking Medicine Technology: